Publication | Closed Access
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
170
Citations
33
References
2011
Year
VTX-2337 is a novel small-molecule TLR8 agonist that activates monocytes, DCs, and NK cells. Through the activation of NK cells, it has the potential to augment the effectiveness of monoclonal antibody treatments where a polymorphism in FcγR3A limits clinical efficacy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1